Diagnostic Challenges in IC (and Male CPPS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-09-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The etiology and pathogenesis of interstitial cystitis (IC) and its related condition in men, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has remained elusive. This has hampered development of mechanistic treatment strategies for these common, chronic and distressing medical conditions. We believe that IC and perhaps CP/CPPS are a spectrum of complex but inter-related genetic and acquired diseases resulting from the interaction of several genes regulating immune/inflammatory and neurogenic parameters and environmental factors/circumstances or exposure, culminating in the combination of pain, frequency, urgency and sexual specific symptoms. New research has delineated the dynamic and powerful association of the immune and neurogenic system in pain activation. An immune-modulated neurogenic model of IC illuminating the action of immune derived substances and pain related substances might be important in discovering the determinants of pain, voiding dysfunction and gender specific sexual problems. This inter-related dynamic model of IC disease pathogenesis could be explored for potential avenues leading to novel diagnostic and treatment strategies. We plan to identify and evaluate the sensitivity and specificity of several novel nerve and inflammation related markers in the diagnosis and follow up of IC (and CP/CPPS). By correlating the levels of urine immune and pain related substances to disease mechanisms, severity and progression, we may be able to create a human disease specific model for diagnosis and treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Linkage Analysis in Interstitial Cystitis

NCT00675298

Prostatitis Cystitis, Interstitial Urinary Bladder, Overactive +2 more

COMPLETED

Microbiome of Urologic Chronic Pelvic Pain Syndrome

NCT03027076

Prostatitis Chronic Prostatitis Interstitial Cystitis +2 more

WITHDRAWN

Microbiomes of Pelvic Pain

NCT01738464

Interstitial Cystitis Chronic Prostatitis Chronic Pelvic Pain Syndrome +3 more

COMPLETED

Chronic Pelvic Pain Study of Individuals With Diagnoses or Symptoms of Interstitial Cystitis and/ or Chronic Prostatitis

NCT01098279

Interstitial Cystitis Chronic Prostatitis

COMPLETED

Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment

NCT06299683

Chronic Interstitial Cystitis Bladder Pain Syndrome Painful Bladder Syndrome +8 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Prostatitis With Chronic Pelvic Pain Syndrome Chronic Bacterial Prostatitis Asymptomatic Inflammatory Prostatitis Painful Bladder Syndrome Cystitis, Interstitial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Chronic prostatitis/chronic pelvic pain syndrome patients

Genomic and proteomic biomarker discovery

Intervention Type GENETIC

Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods

B

Painful bladder syndrome/interstitial cystitis patients

Genomic and proteomic biomarker discovery

Intervention Type GENETIC

Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods

C

Asymptomatic controls

Genomic and proteomic biomarker discovery

Intervention Type GENETIC

Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genomic and proteomic biomarker discovery

Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant has signed and dated the appropriate Informed Consent document.
* Participant must have had symptoms of discomfort or pain in the pelvic region for at least a three (3) month period within the last six (6) months.